<--- Back to Details
First PageDocument Content
Blindness / Macular degeneration / Choroidal neovascularization / Ranibizumab / Vascular endothelial growth factor / Bevacizumab / Drusen / Macula of retina / Retinal pigment epithelium / Medicine / Ophthalmology / Vision
Date: 2014-05-20 00:06:48
Blindness
Macular degeneration
Choroidal neovascularization
Ranibizumab
Vascular endothelial growth factor
Bevacizumab
Drusen
Macula of retina
Retinal pigment epithelium
Medicine
Ophthalmology
Vision

MD Research News Issue 181 Tuesday 20 May, 2014 This free weekly bulletin lists the latest published research articles on macular degeneration (MD) and some

Add to Reading List

Source URL: www.mdfoundation.com.au

Download Document from Source Website

File Size: 196,16 KB

Share Document on Facebook

Similar Documents

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

DocID: 1v2t4 - View Document

Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

DocID: 1t4Bh - View Document

Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Minu K. Srivastava, Chr

Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Minu K. Srivastava, Chr

DocID: 1sS2d - View Document

Theranostics 2016, Vol. 6, Issue 11  Ivyspring International Publisher  Research Paper

Theranostics 2016, Vol. 6, Issue 11 Ivyspring International Publisher Research Paper

DocID: 1qwzN - View Document

APPLI CATI O N N O T E  Exploring gene promoters for experimentally-proven and putative transcription factor binding sites with TRANSFAC® Professional and the included Match™ tool TRANSFAC® Professional is a unique k

APPLI CATI O N N O T E Exploring gene promoters for experimentally-proven and putative transcription factor binding sites with TRANSFAC® Professional and the included Match™ tool TRANSFAC® Professional is a unique k

DocID: 1q7G9 - View Document